News

Patients with neurological sequelae from COVID-19 were significantly more likely to die before discharge (22.2%) compared with non-neuro-COVID patients (14.4%).

Participants will be enrolled for 18 months, with baseline data provided and compared to the lecanemab phase 2 study cohort.

Investigators found occurrence of DDIs through alterations in cytochrome P450 isoenzyme activity, which can be complicated by genetic polymorphism for metabolic enzymes.

The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

The assistant professor of neurology at Harvard Medical School detailed his recent review involving the diagnosis and management of posttraumatic headache with associated cranial neuralgias.

Findings were consistent with recent reports from the Sleep Apnea Global Interdisciplinary Consortium; however, significant differences were identified in comparison to White participants.

Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.

The assistant professor of neurology at Harvard Medical School discussed the motivation behind uncovering more about painful cranial neuralgias and their association with posttraumatic headache.

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.

Pooled data from the phase 3 clinical development of aducanumab (Aduhelm; Biogen) suggest that ARIA remains a mostly asymptomatic problem, with MRI providing an effective way to monitor events.

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Following the publication of new guidelines for the care of adults poststroke, the president of the American Heart Association commented on streamlining systems of care to manage acute stroke and foster long-term prevention.

Many applicants referenced an early interest and exposure to neurology, often describing their first courses in neurology sparking their desire to learn more about how the brain works.

The president of the American Heart Association spoke on the newly published scientific statement and its implications for the clinical stroke treating community.

Here's what is coming soon to NeurologyLive.

The chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.

The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed how much a patients prognosis plays into the treatments utilized.

Investigators observed declines in delayed verbal recall in 20% to 30% of individuals who underwent a dominant temporal lobe resection for treatment of epilepsy.

Neurology News Network for the week ending July 24, 2021.

Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

Alfred Sandrock, MD, PhD, head of research and development, Biogen, has published an open letter to the Alzheimer community in an attempt to clarify “misinformation and misunderstanding” that has moved “outside the boundaries of legitimate scientific deliberation.”

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease commented on social determinants of health in relation to telemedicine and community willingness to engage.

The Integrated Cognitive Assessment showed convergent validity with both MoCA and ACE and offers potential for remote measurement of cognitive performance in Alzheimer disease and mild cognitive impairment.

Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and president, AASM, discussed the state of research in sleep medicine and the gaps in care that need to be addressed.